The value of PFS36 as a primary endpoint for radiotherapy trials in patients with LACC: individual patient data from the Chinese NCC and validation from 26 RCTs [0.03%]
III期宫颈癌患者放疗临床试验的首要终点PFS36的价值：中国NCC个体患者数据分析及26个RCT的验证数据
Xi Yang,Yuanyuan Zhang,Shuangzheng Jia et al.
Xi Yang et al.
Objective: A conventional endpoint for locally advanced cervical cancer (LACC) clinical trials is overall survival (OS) with five years of follow-up. The primary hypothesis was that progression-free survival (PFS) with th...
The single-cell immune landscape of HIV-associated aggressive B-cell lymphoma [0.03%]
HIV相关侵袭性B细胞淋巴瘤的单细胞免疫图谱
Xiaomei Zhang,Zailin Yang,Xiaoqing Xie et al.
Xiaomei Zhang et al.
Background: Human immunodeficiency virus (HIV)-associated lymphomas (HAL), mainly aggressive B-cell lymphomas, pose a significant challenge in cancer research due to their multifaceted pathogenesis and aggressive clinical...
Advance and challenge of DNA methylation as cancer biomarkers for risk stratification, screening and early detection [0.03%]
DNA甲基化在癌症风险分层、筛查和早期检测中的进展与挑战
Na Li,Kai Song,Hongda Chen et al.
Na Li et al.
Indoleamine 2,3-dioxygenase 1-mediated immune suppressive status is positively associated with brain metastasis in patients with non-small cell lung cancer [0.03%]
色氨酸酶IDO1介导的免疫抑制状态与非小细胞肺癌脑转移的积极相关性研究
Weiwei Chen,Li Yang,Victor Ho-Fun Lee et al.
Weiwei Chen et al.
Background: Indoleamine 2,3-dioxygenase (IDO1) activity, measured by kynurenine/tryptophan (K:T) ratio, is known for its association with distant metastasis and overall survival (OS) in patients with non-small cell lung c...
Lifetime risk of developing and dying from cancer in Henan Province, China: current status, temporal trends, and disparities [0.03%]
中国河南省终生患癌和死于癌症的风险：现状、趋势及差异
Qiong Chen,Shuzheng Liu,Yin Liu et al.
Qiong Chen et al.
Objective: To understand the current status and changing trends in the lifetime risk of residents in Henan Province, China to develop and die from cancer. ...
Circulating tumor DNA as a biomarker of prognosis prediction in colorectal cancer: a systematic review and meta-analysis [0.03%]
循环肿瘤DNA在结直肠癌预后预测中作为生物标志物的系统评价和meta分析研究
Qingxin Zhou,Xiaowei Chen,Baoqi Zeng et al.
Qingxin Zhou et al.
Objective: Circulating tumor DNA (ctDNA) is increasingly being used as a potential biomarker in colorectal cancer (CRC) patients. However, the role of ctDNA in CRC prognosis prediction remains unclear. The objective is to...
Rare transformation from lung adenocarcinoma to sarcomatoid carcinoma mediates resistance to inhibitors targeting different driver oncogenes [0.03%]
肺癌腺癌向肉瘤样癌的罕见转化介导了针对不同驱动致癌基因的抑制剂的耐药性
Lanlan Pang,Weitao Zhuang,Yihua Huang et al.
Lanlan Pang et al.
Background: Phenotypic transition is a common resistance mechanism of targeted therapy. While transformations from lung adenocarcinoma (LUAD) to small-cell lung cancer or squamous-cell carcinoma have been extensively stud...
Unraveling molecular interconnections and identifying potential therapeutic targets of significance in obesity-cancer link [0.03%]
解开肥胖与癌症之间的分子联系并识别潜在的治疗靶点
Alanoud Abdulla,Hana Q Sadida,Jayakumar Jerobin et al.
Alanoud Abdulla et al.
Obesity, a global health concern, is associated with severe health issues like type 2 diabetes, heart disease, and respiratory complications. It also increases the risk of various cancers, including melanoma, endometrial, prostate, pancreat...
Chinese expert consensus on flow cytometric detection of hematological malignant cells in tissue samples [0.03%]
组织标本中造血系统恶性肿瘤细胞流式细胞术检测中国专家共识
Zailin Yang,Xia Mao,Mingxia Zhu et al.
Zailin Yang et al.
Flow cytometry (FCM), characterized by its simplicity, rapid processing, multiparameter analysis, and high sensitivity, is widely used in the diagnosis, treatment, and prognosis of hematological malignancies. FCM testing of tissue samples n...